Han W, Ding P, Xu M, Wang L, Rui M, Shi S, et al. Identification of eight genes encoding chemokine-like factor superfamily members 1–8 (CKLFSF1–8) by in silico cloning and experimental validation. Genomics. 2003;81:609–17.

Article  CAS  PubMed  Google Scholar 

Jin C, Ding P, Wang Y, Ma D. Regulation of EGF receptor signaling by the MARVEL domain-containing protein CKLFSF8. FEBS Lett. 2005;579:6375–82.

Article  CAS  PubMed  Google Scholar 

Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549:101–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mezzadra R, Sun C, Jae LT, Gomez-Eerland R, de Vries E, Wu W, et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature. 2017;549:106–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guan X, Zhang C, Zhao J, Sun G, Song Q, Jia W. CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas. EBioMedicine. 2018;35:233–43.

Article  PubMed  PubMed Central  Google Scholar 

Chen L, Yang QC, Li YC, Yang LL, Liu JF, Li H, et al. Targeting CMTM6 suppresses stem cell-like properties and enhances antitumor immunity in head and neck squamous cell carcinoma. Cancer Immunol Res. 2020;8:179–91.

Article  CAS  PubMed  Google Scholar 

Martinez-Morilla S, Zugazagoitia J, Wong PF, Kluger HM, Rimm DL. Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy. Oncoimmunology. 2020;10:1864909.

Article  PubMed  PubMed Central  Google Scholar 

Wu X, Lan X, Hu W, Zhang W, Lai X, Xu S, et al. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer. Cancer Immunol Immunother. 2021;70:3235–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li X, Chen L, Gu C, Sun Q, Li J. CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients. PeerJ. 2020;8:e9536.

Article  PubMed  PubMed Central  Google Scholar 

Zhao Y, Zhang M, Pu H, Guo S, Zhang S, Wang Y. Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment. Front Oncol. 2020;10:585961.

Article  PubMed  Google Scholar 

Zheng Y, Wang C, Song A, Jiang F, Zhou J, Li G, et al. CMTM6 promotes cell proliferation and invasion in oral squamous cell carcinoma by interacting with NRP1. Am J Cancer Res. 2020;10:1691–709.

CAS  PubMed  PubMed Central  Google Scholar 

Wang H, Fan Y, Chen W, Lv Z, Wu S, Xuan Y, et al. Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity. Oncoimmunology. 2022;11:2011673.

Article  PubMed  PubMed Central  Google Scholar 

Mohapatra P, Shriwas O, Mohanty S, Ghosh A, Smita S, Kaushik SR, et al. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3beta axis. JCI Insight. 2021;6:e143643.

PubMed  PubMed Central  Google Scholar 

Pang X, Wang SS, Zhang M, Jiang J, Fan HY, Wu JS, et al. OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway. Cancer Immunol Immunother. 2021;70:1015–29.

Article  CAS  PubMed  Google Scholar 

Huang Y, Zhu Y, Yang J, Pan Q, Zhao J, Song M, et al. CMTM6 inhibits tumor growth and reverses chemoresistance by preventing ubiquitination of p21 in hepatocellular carcinoma. Cell Death Dis. 2022;13:251.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Z, Peng Z, Liu Q, Guo Z, Menatola M, Su J, et al. Co-expression with membrane CMTM6/4 on tumor epithelium enhances the prediction value of PD-L1 on Anti-PD-1/L1 therapeutic efficacy in gastric adenocarcinoma. Cancers (Basel). 2021;13:5175.

Article  CAS  PubMed  Google Scholar 

Althoff T, Mills DJ, Popot JL, Kühlbrandt W. Arrangement of electron transport chain components in bovine mitochondrial supercomplex I1III2IV1. EMBO J. 2011;30:4652–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kevany BM, Tsybovsky Y, Campuzano ID, Schnier PD, Engel A, Palczewski K. Structural and functional analysis of the native peripherin-ROM1 complex isolated from photoreceptor cells. J Biol Chem. 2013;288:36272–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsybovsky Y, Orban T, Molday RS, Taylor D, Palczewski K. Molecular organization and ATP-induced conformational changes of ABCA4, the photoreceptor-specific ABC transporter. Structure. 2013;21:854–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang EY, Shah K. Nanobodies: Next generation of cancer diagnostics and therapeutics. Front Oncol. 2020;10:1182.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahuja S, Rougé L, Swem DL, Sudhamsu J, Wu P, Russell SJ, et al. Structural analysis of bacterial ABC transporter inhibition by an antibody fragment. Structure. 2015;23:713–23.

Article  CAS  PubMed  Google Scholar 

Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood. 2008;111:3635–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lan Y, Zhang D, Xu C, Hance KW, Marelli B, Qi J, et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β. Sci Transl Med. 2018;10:eaan5488.

Article  PubMed  Google Scholar 

Miao YR, Zhang Q, Lei Q, Luo M, Xie GY, Wang H, et al. ImmuCellAI: A unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy. Adv Sci (Weinh). 2020;7:1902880.

Article  CAS  PubMed  Google Scholar 

Maute RL, Gordon SR, Mayer AT, McCracken MN, Natarajan A, Ring NG, et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci USA. 2015;112:E6506–E6514.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng X, Veverka V, Radhakrishnan A, Waters LC, Muskett FW, Morgan SH, et al. Structure and interactions of the human programmed cell death 1 receptor. J Biol Chem. 2013;288:11771–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52:17–35.

Article  CAS  PubMed  Google Scholar 

Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76:359–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang H, Yao H, Li C, Shi H, Lan J, Li Z, et al. HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity. Nat Chem Biol. 2019;15:42–50.

Article  CAS  PubMed  Google Scholar 

Ren Y, Qian Y, Ai L, Xie Y, Gao Y, Zhuang Z, et al. TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity. Nat Commun. 2021;12:5405.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Y, Liu P, Gao F, Cheng H, Qi J, Gao GF. A dimeric structure of PD-L1: functional units or evolutionary relics? Protein Cell. 2010;1:153–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zak KM, Grudnik P, Magiera K, Dömling A, Dubin G, Holak TA. Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1/PD-L2. Structure. 2017;25:1163–74.

Article  CAS  PubMed  Google Scholar 

Zak KM, Grudnik P, Guzik K, Zieba BJ, Musielak B, Dömling A, et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget. 2016;7:30323–35.

Article  PubMed  PubMed Central  Google Scholar 

Guo Y, Jin Y, Wang B, Liu B. Molecular mechanism of small-molecule inhibitors in blocking the PD-1/PD-L1 pathway through PD-L1 dimerization. Int J Mol Sci. 2021;22:4766.